Oct 09 2026 09:44 PM EST
Viatris Deal Propels Pacira Shares Higher as Investors Reassess Valuation
Pacira BioSciences (NASDAQ: PCRX) surged roughly 44% after Viatris announced a definitive agreement to acquire the company for $36.50 per share in cash, bringing the stock to the offer price of about $36.30. The rally followed a prior 4.7% gain earlier in August when several analysts upgraded the stock. The combined moves lifted Pacira toward a market capitalization of roughly $1.45 billion.
In the quarter ended June 30, 2026, Pacira reported total revenue of $192.4 million, a 6% YoY increase driven by EXPAREL ($147.8 million) and ZILRETTA ($32.6 million). GAAP diluted EPS turned positive at $0.12, and GAAP net income rose to $4.7 million from a loss a year earlier. Adjusted EBITDA stood at $48.7 million. Cash and investments were $251 million at quarter‑end, excluding the $73.6 million proceeds from the iovera divestiture that closed on July 31, 2026.
Acquisition Announcement and Market Reaction
The Viatris offer of $36.50 per share represents a premium of roughly 23% to the prior closing price. Analysts quickly aligned their price targets with the deal, with JPMorgan Chase raising its target to $36.50 and Needham adjusting its rating to Hold. The consensus target now implies upside of about 43% from the pre‑announcement level. The transaction also promises up to $140 million in additional milestones, providing a tangible cash‑flow upside.
Quarterly Results Reinforce Fundamentals
Revenue growth was modest, but the shift to positive GAAP earnings signaled improving profitability. GAGAAP gross margin held at 77%, while non‑GAAP gross margin slipped to 78% from 82% a year earlier after a one‑time manufacturing‑suite charge. Operating expenses rose 9% to $188.1 million, reflecting higher SG&A and a $5.9 million charge related to the iovera divestiture. The company reaffirmed FY 2026 revenue guidance of $735‑$760 million, essentially unchanged after removing iovera sales.
Strategic Partnerships and Industry Tailwinds
Pacira’s non‑opioid pain franchise benefits from the NOPAIN Act, which boosted Medicare reimbursement for non‑opioid analgesics in outpatient settings. UnitedHealthcare recently began separate reimbursement for EXPAREL in hospital outpatient departments and ambulatory surgery centers, covering a plan with roughly 40 million lives. Internationally, a new exclusive commercial agreement with Molteni Farmaceutici will launch EXPAREL in several European markets in 2027, and an Asia‑Pacific partnership with LG Chem expands the product’s reach in the region. These deals broaden the addressable market beyond the United States.
Valuation and Analyst Outlook
Prior to the Viatris announcement, the stock traded at a forward P/E of roughly 10.6× and a GuruFocus intrinsic value of $29.38, indicating a 23.5% premium to intrinsic value. After the deal, the price aligns with the offer, narrowing the valuation gap but leaving the equity at a high multiple relative to historical earnings. The consensus target range of $31‑$33 now sits below the transaction price, reinforcing the perception of a premium‑priced acquisition.
Risks and Uncertainties
Key risks include integration uncertainty after the Viatris merger, which could affect commercial execution and cost synergies. The stock’s high valuation leaves limited upside if post‑deal earnings growth slows. Short interest remains elevated at roughly 21.6% of float, exposing the share price to potential short‑cover dynamics. Additionally, any slowdown in UnitedHealthcare or other payer reimbursement, as well as execution of international partnerships, could temper revenue growth.